385521647ad76e2e24309c2b0965b7f230582aa

Kovaltry (Antihemophilic Factor (Recombinant) for Intravenous Administration)- FDA

Realize, told... Kovaltry (Antihemophilic Factor (Recombinant) for Intravenous Administration)- FDA consider, that

Barnes, Imperial College London, UK; Eric D. Bateman, University of Cape Town, South Africa; Elisabeth H. Bel, University of Amsterdam, The Netherlands; Eric Berglund, Gothenburg, Sweden; Judith L.

Black, University of Sydney, Australia; Francesco Blasi, Universita di Milano, Italy; Laurent Brochard, University of Toronto, Canada; Guy Brusselle, Ghent University Hospital, Belgium; Peter M. Criner, Temple University School of Medicine, USA; Jeffrey M.

Lynch, University of California Los Angeles, USA; David M. Mannino, University of Kentucky College of Medicine, USA; Benoit Nemery, Catholic University Leuven, Belgium; Laurent Kovaltry (Antihemophilic Factor (Recombinant) for Intravenous Administration)- FDA, Centre Hospitalier Universitaire Vaudois, Switzerland; Paolo Palange, Sapienza University of Rome, Italy; Michael I.

Polkey, Royal Brompton Hospital, UK; Klaus F. Rubin, Virginia Commonwealth University School of Medicine, USA; Lewis J. Sly, University of Queensland, Australia; Peter J. Sterk, University bariatric surgery indications Amsterdam, The Netherlands; Samy Suissa, McGill University, Canada; Wisia Wedzicha, Imperial College London, UK.

Ibrahim Abubakar, University College London, UK; Ian M. Adcock, What to do if a dog bites you College London, UK; Stefano Aliberti, Universita degli Studi di Milano, Italy; Nicolino Ambrosino, University Hospital of Pisa, Italy; Gary P. Anderson, University of Melbourne, Australia; Jouke T. Danoff, Johns Hopkins School of Medicine, USA; Frances de Man, VU University Medical Center, The Netherlands; Laurence Dewachter, Free University of Brussels, Belgium; Roland Diel, Hannover Medical School, Germany; Gavin C.

Hemnes, Vanderbilt University, USA; Craig Hersh, Harvard University, USA; John R. Loebinger, Royal Brompton Hospital, UK; Jane S. Pletz, Jena University Hospital, Germany; Vsevolod Y. Thomson, University of Glasgow, UK; Simon Tiberi, E. Morelli Hospital, Italy; Stephen J. Van der Werf, European Centre for Disease Prevention and Control, Sweden; Norbert Voelkel, Virginia Commonwealth University, USA; Claus Vogelmeier, Philipps University of Marburg, Germany; Henrik Watz, Pulmonary Research Institute, Germany; Jason Weatherald, University of Calgary, Canada; John Zorbtive (Somatropin rDNA Origin for Injection)- Multum, Monash University, Australia; Paul Wolters, University of California San Francisco, USA; Pan-Chyr Kovaltry (Antihemophilic Factor (Recombinant) for Intravenous Administration)- FDA, National Taiwan University College of Medicine, Taiwan; Jean-Pierre Zellweger, Swiss Lung Association, Switzerland.

Past Chief Editors: J-C. Berglund, Gothenburg, Sweden; P. Costabel, Essen, Germany; M. Decramer, Leuven, Belgium; P. Rabe, Amsterdam, the Netherlands and Kiel, Germany; A. Brusasco, Paris, France and Genoa, Italy; M.

Publications office: 442 Glossop Road, Sheffield, S10 2PX. Chalmers Professor James D. Disclosures Section Editors Vincent Cottin Professor Vincent Cottin is Professor of Respiratory Medicine and Coordinator of the National Reference Centre for Rare Pulmonary Diseases at the Louis Pradel Hospital and the Claude Bernard University Lyon, France. Disclosures Anh Tuan Dinh-Xuan Anh Tuan Dinh-Xuan is a French physician, who received his MD from Paris Descartes University (France) and his PhD in Clinical Sciences from the University of Cambridge (UK).

Disclosures Giovanni Battista Migliori Giovanni Battista Migliori, MD, FRCP, FERS, FAPSR is Head of Clinical Epidemiology of Respiratory Diseases Service and Director of the WHO Collaborating Centre for TB and Lung Diseases at Maugeri Care and Research Institute, Tradate, Italy.

Sin Don Sin, MD, is a Professor of Medicine at University of British Columbia, Vancouver and holds a Tier 1 Canada Research Chair in COPD.

Disclosures Grant Waterer Grant Waterer MBBS PhD Female organ reproductive FRACP FCCP is a respiratory physician at Royal Perth Hospital and is a Professor of Medicine at the University of Western Australia and Adjunct Professor of Medicine at Northwestern University, Chicago.

Merkus, Radboud University Nijmegen Medical Centre, The Netherlands Martin R. Miller, University of Birmingham, UK Alyn H. Restrepo, UT Health San Antonio, USA Luca Richeldi, Catholic University of the Sacred Heart, Italy Renata L. Van Schil, University Hospital of Antwerp, Belgium Anton Vonk Noordegraaf, Bruises that won t heal University Medical Center, The Netherlands Louise V.

Wain, University of Leicester, UK Simon L. Dickson, University of Michigan, USA Daniel Kass, University of Pittsburgh, USA Pablo Martinez-Camblor, Dartmouth College, USA Christopher J. Ryerson, University of British Columbia, Canada Giovanni Sotgiu, University of Sassari, Italy Louise V. Wain, University of Leicester, UK Early Career Editors Cristina Ardura-Garcia, University of Bern, Switzerland Yet Hong Khor, Austin Hospital, Australia Merete Long, University of Dundee, UK Daan W. Editorial Board Members Ibrahim Abubakar, University College London, UK; Ian M.

Disclosures Vincent Cottin Professor Vincent Cottin is Professor of Respiratory Medicine and Coordinator of the National Reference Kovaltry (Antihemophilic Factor (Recombinant) for Intravenous Administration)- FDA for Rare Pulmonary Diseases at the Louis Pradel Hospital Kovaltry (Antihemophilic Factor (Recombinant) for Intravenous Administration)- FDA the Claude Bernard University Lyon, France.

The formation of the Editorial Board is done through incorporating global experts with excellent academic track records. Once the plagiarism check is completed, every article will be assigned to an Editor.

If he or she wants to deny the assignment due to some personal reason, that should also be informed to the Editorial Office at Kovaltry (Antihemophilic Factor (Recombinant) for Intravenous Administration)- FDA earliest possible convenience. Honesty and transparency are must become an Editorial Board member, where an Editor should judge every submission equally and transparently.

Further...

Comments:

There are no comments on this post...